clinicalomicsprowebdirectory
News & Features
Topics
Precision Medicine
Translational Research
Molecular Dx
Informatics
Oncology
Patient Care
New Products
Magazine
Multimedia
Webinars
eBooks
Subscribe
Create a Free Account
Log In
Get Clinical OMICs Magazine
Get Clinical OMICs eNewsletters
Get the Clinical OMICs Mobile App
Get Clinical OMICs News from Alexa
Search
Advertise
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Lead Generation Campaigns
Email Nurture Campaigns
Custom Content Solutions
About Us
Contact Us
Mary Ann Liebert Publishers
Create a Free Account
Log In
Clinical OMICs – Molecular Diagnostics in Precision Medicine
News & Features
Molecular Dx
Nanomix Gets $570K from BARDA to Develop Rapid, POC COVID-19 Tests
Patient Care
A4 Study: Elevated Amyloid an early Sign of Alzheimer’s Disease
Precision Medicine
BillionToOne Goes Beyond qPCR with Sanger-Based COVID-19 Test
Oncology
Fate Therapeutics’ IO Collaboration with Janssen Could Yield Company $3 Billion
Patient Care
Coronavirus Replication Stopped in 48 Hours in Lab-Grown Cells by Anti-Parasitic…
Topics
All
Precision Medicine
Translational Research
Molecular Dx
Informatics
Oncology
Patient Care
New Products
Molecular Dx
Nanomix Gets $570K from BARDA to Develop Rapid, POC COVID-19 Tests
Patient Care
A4 Study: Elevated Amyloid an early Sign of Alzheimer’s Disease
Precision Medicine
BillionToOne Goes Beyond qPCR with Sanger-Based COVID-19 Test
Oncology
Fate Therapeutics’ IO Collaboration with Janssen Could Yield Company $3 Billion
Magazine
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 2
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 1
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 6
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 5
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 4
Multimedia
All
Webinars
eBooks
eBooks
Clinical Research in a Real-Time Sequencing Age
Precision Medicine
From Bench to Clinic—The Potential of New Sequencing Tools
Precision Medicine
Mainstreaming Precision Oncology
eBooks
Better Understanding of Post-Translation Modifications Driving Innovation
Subscribe
Create a Free Account
Log In
Get Clinical OMICs Magazine
Get Clinical OMICs eNewsletters
Get the Clinical OMICs Mobile App
Get Clinical OMICs News from Alexa
Home
Companies
Cancer Genetics
Cancer Genetics
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Cancer Genetics
Interpace Diagnostics Buys Cancer Genetics’ BioPharma Business for $23.5M
July 17, 2019
Cancer Genetics
Cancer Genetics Scraps Planned Merger with NovellusDx
December 17, 2018
Cancer Genetics
Cancer Genetics CEO Panna Sharma Steps Down
February 5, 2018
Cancer Genetics
Cancer Genetics Gains $1.1M from NJ Net Operating Loss Program
December 28, 2017
Cancer Genetics
Third Quarter Brings Record Revenue for Cancer Genetics
November 9, 2017
Cancer Genetics
Cancer Genetics to Offer Biomarker Services for eFFECTOR Therapeutics Lead Candidate
April 10, 2017
Cancer Genetics
Ignyta to Use Angsana Cancer Panel in Registrational Trial of Anti-Tumor...
March 3, 2017
Cancer Genetics
Philips Expands Personalized Cancer Collaboration with NYMC
December 7, 2016
Cancer Genetics
University of Michigan Taps Tempus to Commercialize MI-ONCOSEQ Cancer Panel
October 12, 2016
Cancer Genetics
Sanford Health Enrolling Patients for Genomic Profiling Research
October 11, 2016
Load more
Scroll Up
We use cookies to give you a better experience on clinicalomics.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
![Cancer Genetics (CGI) has terminated its planned merger with NovellusDx and will instead “pursue alternative strategic and financial transactions” intended to enhance shareholder value.. [nicolas_ / Getty Imagesnicolas_ / Getty Images]](https://www.clinicalomics.com/wp-content/uploads/2019/01/2051-324x160.jpeg "Cancer Genetics Scraps Planned Merger with NovellusDx")
![Cancer Genetics (CGI) has received $1.1 million in net cash proceeds through the transfer of tax credits approved by the New Jersey Technology Business Tax Certificate Transfer (NOL) program of the New Jersey Economic Development Authority (NJEDA). [Source: Maxim_Kazmin/Fotolia]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1407-324x160.jpeg "Cancer Genetics Gains $1.1M from NJ Net Operating Loss Program")
